29.83

1.81% -0.55

After Hours: 29.83

Arrivent Biopharma Inc (AVBP)

Overview News Price History Discussions Forecast

Arrivent Biopharma Inc stock is traded at $29.83, with a volume of 336.47K. It is down -1.81% in the last 24 hours and up +19.85% over the past month. ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. The company focuses on advancing its lead product candidate, firmonertinib, for the treatment of epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC), and developing a pipeline of novel therapeutics, including next-generation antibody-drug conjugates such as ARR-217 (MRG007), with an initial focus on solid tumors.

Previous Close:

$30.38

Open:

$30.76

24h Volume:

336.47K

Relative Volume:

0.64

Market Cap:

$1.38B

Revenue:

Net Income/Loss:

$-166.31M

P/E Ratio:

-6.688

EPS:

-4.4602

Net Cash Flow:

$-160.59M

1W Performance:

-0.70%

1M Performance:

+19.85%

6M Performance:

+62.74%

1Y Performance:

+43.34%

1-Day Range:

$28.99

$31.18

1-Week Range:

$28.99

$31.87

52-Week Range:

$16.10

$32.14

Arrivent Biopharma Inc Stock (AVBP) Company Profile

Name

Arrivent Biopharma Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

240-780-6356

Address

18 CAMPUS BLVD., NEWTOWN SQUARE

Employee

Twitter

Next Earnings Date

2026-05-11

Latest SEC Filings

AVBP's Discussions on Twitter

Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AVBP Arrivent Biopharma Inc	29.83	1.41B	0	-166.31M	-160.59M	-4.4602
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-12-26	Resumed	BTIG Research	Buy
Dec-10-25	Initiated	BTIG Research	Buy
Nov-25-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Buy
Mar-20-25	Initiated	B. Riley Securities	Buy
Mar-10-25	Initiated	Guggenheim	Buy
Jul-22-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Feb-20-24	Initiated	Citigroup	Buy
Feb-20-24	Initiated	Goldman	Buy
Feb-20-24	Initiated	Jefferies	Buy

View All

Arrivent Biopharma Inc Stock (AVBP) Latest News

Apr 30, 2026

ArriVent BioPharma (NASDAQ: AVBP) details 2026 virtual meeting, board elections and CEO pay - Stock Titan

Apr 28, 2026

Apr 27, 2026

Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained - TipRanks

Apr 27, 2026

Apr 25, 2026

Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Apr 25, 2026

Apr 24, 2026

Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN

Apr 24, 2026

Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00 - MarketBeat

Apr 24, 2026

Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo

Apr 24, 2026

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 24, 2026

Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN

Apr 24, 2026

Apr 23, 2026

Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN

Apr 23, 2026

Apr 22, 2026

ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighWhat's Next? - MarketBeat

Apr 22, 2026

Apr 21, 2026

Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga

Apr 21, 2026

Apr 18, 2026

Stocks generating improved relative strength: ArriVent BioPharma - MSN

Apr 18, 2026

What macro factors move ArriVent (AVBP) stock most (Stalls) 2026-04-18Community Risk Signals - Xã Châu Thành

Apr 18, 2026

Apr 17, 2026

Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com - Investing.com Australia

Apr 17, 2026